Clinical Trial

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia.
Protocol Amendment History 4 changes
notable Trial sites expanded: 26 -> 29 locations 2026-07-31
notable Trial sites expanded: 7 -> 26 locations 2026-06-24
critical Recruitment opened 2026-06-23
notable Trial sites expanded: 0 -> 7 locations 2026-06-23
Trial Details
NCT Number NCT07610278
Lead Sponsor Novartis Pharmaceuticals
Conditions Hypercholesterolaemia
Enrollment 120 participants
Start Date 2026-05-29
Primary Completion 2027-04-28 (estimated)
Study Completion 2028-02-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-30